\nImmunityBio, Inc. (NASDAQ: IBRX<\/a>), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company\u2019s business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials.\n<\/p>\n
\n\u201cImmunityBio commenced 2025 with notable scientific and business milestones,\u201d said Richard Adcock, President and CEO of ImmunityBio. \u201cWith a promising future ahead, we are eager to engage with our investors and share the reasons we\u2019re optimistic and excited about the company\u2019s growth trajectory.\u201d\n<\/p>\n
\nThe program will feature a presentation by ImmunityBio Founder, Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, outlining the fundamental science underpinning the company\u2019s technology platforms. This technology harnesses the immune system to deliver long-term disease protection and prevention.\n<\/p>\n
\n\u201cWe have been relentlessly pursuing an innovative scientific approach to immunology that we believe will revolutionize cancer care,\u201d remarked Dr. Patrick Soon-Shiong. \u201cNot only has this approach produced ANKTIVA, our initial therapeutic, but the future appears bright as we continue our pursuit of developing a Therapeutic BioShield across multiple tumor types.\u201d\n<\/p>\n
\nThis limited space event will be held in person at the company\u2019s facilities in El Segundo, California. A tour of select manufacturing facilities will be provided, showcasing the company\u2019s efficient and scalable production capabilities.\n<\/p>\n
\nIndividuals wishing to attend in person must contact investorday2025@immunitybio.com<\/a>. The event will also be live-streamed.\n<\/p>\n The live stream can be found at Participant Listening (Listen Only) About ImmunityBio<\/b><\/p>\n \nImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company\u2019s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit ImmunityBio.com<\/a> (Founder\u2019s Vision) and connect with us on X<\/a> (Twitter), Facebook<\/a>, LinkedIn<\/a>, and Instagram<\/a>.\n<\/p>\n Forward-Looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the anticipated date, time, location, subject matter and other information regarding the investor day program described herein, ImmunityBio\u2019s potential growth trajectory and business prospects, ImmunityBio\u2019s beliefs regarding the potential for its approach to revolutionize cancer care, ImmunityBio\u2019s manufacturing and production capabilities, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA and use in cancer vaccines and across multiple tumor types, and ImmunityBio\u2019s approved product and its and its collaborators\u2019 investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as \u201canticipates,\u201d \u201cbelieves,\u201d \u201ccontinues,\u201d \u201cgoal,\u201d \u201ccould,\u201d \u201cestimates,\u201d \u201cscheduled,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cpotential,\u201d \u201cpredicts,\u201d \u201cindicate,\u201d \u201cprojects,\u201d \u201cis,\u201d \u201cseeks,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cstrategy,\u201d and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio\u2019s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio\u2019s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks, uncertainties and potential changes in circumstances that may impact ImmunityBio\u2019s ability to hold the investor day program as described herein, (ii) risks and uncertainties regarding commercial launch execution, success and timing, (iii) risks and uncertainties related to the regulatory submission, filing and review process and the timing thereof, (iv) the ability of ImmunityBio to fund its ongoing and anticipated clinical trials, (v) whether clinical trials will result in registrational pathways, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and\/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) the risks and uncertainties associated with third party collaborations and agreements, (x) ImmunityBio\u2019s ability to retain and hire key personnel, (xi) ImmunityBio\u2019s ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xii) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xiii) ImmunityBio\u2019s ability to successfully commercialize its approved product and product candidates, (xiv) ImmunityBio\u2019s ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xv) ImmunityBio\u2019s ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio\u2019s business are described under the heading \u201cRisk Factors\u201d in the Company\u2019s Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC\u2019s website at www.sec.gov<\/a>. ImmunityBio cautions you not to place undue reliance on any forward looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250326159430\/en\/<\/a><\/span><\/p>\n ImmunityBio Contacts: Media KEYWORDS:<\/b> United States North America California<\/p>\n INDUSTRY KEYWORDS:<\/b> Oncology Health Infectious Diseases Clinical Trials Pharmaceutical Biotechnology<\/p>\n
\n
<\/span><\/b>https:\/\/viavid.webcasts.com\/starthere.jsp?ei=1713505&tp_key=40dc7065b5<\/a><\/p>\n
\n
<\/span><\/b>1-844-539-3703 or 1-412-652-1273\n<\/p>\n<\/p>\n
\n<\/b>
Investors
\n<\/b>
Hemanth Ramaprakash, PhD, MBA
\n<\/b>
ImmunityBio, Inc.
\n<\/b>
+1 858-746-9289
\n
Hemanth.Ramaprakash@ImmunityBio.com<\/a><\/p>\n
\n<\/b>
Sarah Singleton
\n<\/b>
ImmunityBio, Inc.
\n<\/b>
+1 415-290-8045
\n
Sarah.Singleton@ImmunityBio.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20250326159430\/en\/1463552\/3\/BusinessWire_-ImmunityBio.jpg\")
<\/td>\n<\/tr>\n